Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Over 100 patients treated with AlloNK across autoimmune and oncology indications

Refractory rheumatoid arthritis (RA) prioritized as lead indication following FDA Fast Track Designation for AlloNK®, the first known therapy within the emerging deep B-cell depletion category to receive this designation in RA

Read more at globenewswire.com